The 12-week dosing regimen was retrieved from the FDA approved label for each drug. The payment limit for drugs that can be taken for an indefinite period of time was applied to a 12-week dosing regimen for an “average” adult weighing 70kg, or with a body surface area of 1.7 square meters, and divided by 2.77 to arrive at a monthly price.
If a drug’s ASP is not available, Medicare calculates the payment limit as 95% of the Average Wholesale Price (AWP).
#Abacus for sale multiple wholesale code#
The price reported is the “Full Cost of Drug” as reported in the PlanFinder for the Humana PDP Enhanced plan for a beneficiary living within ZIP code 10065. For Part D drugs, current prices were retrieved from Medicare’s publicly available PlanFinder tool. The reduction in reimbursement due to the 2013 ‘sequester,’ which lowered reimbursement to ASP+4.2%, is not included in these calculations. Payment limits are reported in quarterly files released by CMS. Current PricesĮstimated monthly prices for the US market were calculated according to a methodology used in prior reports based on the Medicare payment limit-106% of the Average Sales Price (ASP) for Part B drugs. While the characteristics of most drugs in the Drug Abacus are based on information related to the first approved indication, four drugs (Afinitor, Avastin, Nexavar, and Tarceva) in the new indication specific pricing feature include information for supplemental indications. The Drug Abacus covers 52 cancer drugs approved by the FDA between 20, most of which were compiled from Howard et al., with supplemental drugs and indications added after 2013. Methods Selection of Drugs and Indications
0 kommentar(er)
